Screening for type 2 diabetes: A short report for the National Screening Committee

Health Technology Assessment

Volumn 17, Issue 35, 2013, Pages 1-89

  Waugh, N R ^a   Shyangdan, D ^a   Taylor Phillips, S ^a   Suri, G ^a   Hall, B ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

AFRICAN CARIBBEAN; AGE DISTRIBUTION; ASIAN; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DIABETES MELLITUS; DIABETIC DIET; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; FINNISH DIABETES RISK SCORE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH PROMOTION; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MASS SCREENING; MEDICAL AUDIT; MEDICAL DECISION MAKING; METABOLIC DISORDER; MOTIVATIONAL INTERVIEWING; NATIONAL HEALTH SERVICE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PROFESSIONAL STANDARD; QDIABETES RISK SCORE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SOUTH ASIA; TREATMENT INDICATION; UNITED KINGDOM; WEIGHT REDUCTION;

ADULT; AGE DISTRIBUTION; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; MALE; MASS SCREENING; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREDIABETIC STATE; PREVALENCE; RISK ASSESSMENT;

EID: 84883468833     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17350     Document Type: Review

References (163)

1. UKPDS Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. Looker HC, Nyangoma SO, Cromie D, Olson JA, Leese GP, Black M, et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 2012;55:2335-42.
3. Pierce MB, Zaninotto P, Steel N, Mindell J. Undiagnosed diabetes: data from the English longitudinal study of ageing. Diabet Med 2009;26:679-85. http://dx.doi.org/10.1111/j.1464-5491.2009.02755.x
4. Goyder E, Wild S, Fischbacher C, Carlisle J, Peters J. Evaluating the impact of a national pilot screening programme for type 2 diabetes in deprived areas of England. Fam Pract 2008;25:370-5. http://dx.doi.org/10.1093/fampra/cmn054
5. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB, Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-74. http://dx.doi.org/10.1001/archinte.167.10.1068
6. Grant I, Fischbacher C, Whyte B. Scottish Public Health Observatory (ScotPHO) collaboration. Obesity in Scotland: an epidemiology briefing. 2007. URL: www.scotpho.org.uk/home/Publications/ scotphoreports/pub_obesityinscotland.asp. Accessed 15 May 2012.
7. Yorkshire & Humber Public Health Observatory (YHPHO). Diabetes key facts. 2006. URL: www.yhpho.org.uk/resource/item.aspx?RID=8872. Accessed 18 June 2012.
8. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997;146:214-22. http://dx.doi.org/10.1093/oxfordjournals. aje.a009256
9. Echouffo-Tcheugui JB, Sargeant LA, Prevost AT, Williams KM, Barling RS, Butler R, et al. How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabet Med 2008;25:1433-9. http://dx.doi.org/10.1111/j.1464-5491.2008.02600.x
10. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, et al. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess 2007;11(17).
11. UK National Screening Committee. Programme appraisal criteria. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2012. URL: www.screening.nhs.uk/ criteria. Accessed 20 February 2012.
12. National Audit Office (NAO). The management of adult diabetes services in the NHS. Department of Health, 2012. URL: www.nao.org.uk/publications/1213/adult_diabetes_services.aspx. Accessed 18 June 2012.
13. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. Effect of screening for type 2 diabetes on population-level self-rate health outcomes and measures of cardiovascular risk: 13 year follow-up of the Ely cohort. Diabet Med 2012;29:886-92.
14. Mozaffarian D, Kamineni A, Carnethon M, Djousse L, Mukamal KJ, Siscovick D. Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 2009;169:798-807. http://dx.doi.org/10.1001/archinternmed.2009.21
15. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. http://dx.doi.org/10.1056/NEJM200105033441801
16. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9. http://dx.doi.org/10.1016/S0140-6736(06) 69701-8
17. UK National Screening Committee. DPH newsletter. 2008. URL: www.screening.nhs.uk/ publications-archive. Accessed 15 May 2012.
18. Diabetes UK Cymru. Welsh pharmacies offered type 2 diabetes assessments. 2011. URL: www.diabetes.org.uk/In_Your_Area/Wales/Campaigning/Pharmacy-campaign. Accessed 16 February 2012.
19. Gillett MF, Royle PF, Snaith AF, Scotland GF, Poobalan AF, Imamura MF, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess 2012;16(33).
20. Gavin II, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
21. Colagiuri S, Lee CM, Wong TY, Wong TY, Balkau B, Shaw JE, et al. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145-50. http://dx.doi.org/10.2337/dc10-1206
22. Diabetes Prevention Program Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137-44.
23. Chamnan P, Simmons RK, Jackson R, Khaw KT, Wareham NJ, Griffin SJ. Non-diabetic hyperglycaemia and cardiovascular risk: moving beyond categorisation to individual interpretation of absolute risk. Diabetologia 2011;54:291-9. http://dx.doi.org/10.1007/s00125-010-1914-6
24. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. http://dx.doi.org/10.1136/bmj.321.7258.405
25. UKPDS Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
26. Balkau B. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004;47:2118-28.
27. Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010;33:2211-16. http://dx.doi.org/10.2337/dc09-2328
28. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40. http://dx.doi.org/10.2337/ diacare.22.2.233
29. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.
30. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Medicine 2010;7:e1000278. http://dx.doi.org/10.1371/journal. pmed.1000278
31. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009;52:415-24. http://dx.doi.org/ 10.1007/s00125-008-1246-y
32. Wild SH, Smith FB, Lee AJ, Fowkes FG. Criteria for previously undiagnosed diabetes and risk of mortality: 15-year follow-up of the Edinburgh Artery Study cohort. Diabet Med 2005;22:490-6. http://dx.doi.org/10.1111/j.1464-5491.2004.01433.x
33. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31. http://dx.doi.org/10.1007/s001250051249
34. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-9. http://dx.doi.org/10.2337/diacare.21.8.1236
35. Charles MA, Balkau B, Vauzelle-Kervroedan F, Thibult N, Eschwege E. Revision of diagnostic criteria for diabetes. Lancet 1996;348:1657-8. http://dx.doi.org/10.1016/S0140-6736(05)65719-4
36. Davies MJ, Gray IP. Impaired glucose tolerance. BMJ 1996;312:264-5. http://dx.doi.org/10.1136/ bmj.312.7026.264
37. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004;141:413-20. http://dx.doi.org/10.1016/j.accreview.2004.11.074
38. Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw KT, Wareham NJ, et al. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 2008;168:1209-16. http://dx.doi.org/10.1001/archinte.168.11.1209
39. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009;52:2001-14. http://dx.doi.org/ 10.1007/s00125-009-1454-0
40. Novoa FJ, Boronat M, Saavedra P, Diaz-Cremades JM, Varillas VF, La RF, et al. Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 2005;28:2388-93. http://dx.doi.org/10.2337/diacare.28.10.2388
41. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care 2005;28:1981-7. http://dx.doi.org/10.2337/ diacare.28.8.1981
42. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004;27:727-33. http://dx.doi.org/10.2337/diacare.27.3.727
43. Paulweber B, Valensi P, Lindstrom J, Lalic NM, Greaves CJ, McKee M, et al. A European evidencebased guideline for the prevention of type 2 diabetes. Horm Metab Res 2010;42(Suppl. 1):S3-36. http://dx.doi.org/10.1055/s-0029-1240928
44. Bergmann A, Li J, Wang L, Schulze J, Bornstein SR, Schwarz PE. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res 2007;39:677-82. http://dx.doi.org/10.1055/s-2007-985353
45. Franciosi M, De BG, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 2005;28:1187-94. http://dx.doi.org/10.2337/diacare.28.5.1187
46. Tan HH, McAlpine RR, James P, Thompson P, McMurdo MET, Morris AD, et al. Diagnosis of type 2 diabetes at an older age: Effect on mortality in men and women. Diabetes Care 2004;27:2797-9. http://dx.doi.org/10.2337/diacare.27.12.2797
47. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74. http://dx.doi.org/10.1016/S0140-6736(09)62162-0
48. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001;24:1377-83. http://dx.doi.org/10.2337/diacare.24.8.1377
49. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-31. http://dx.doi.org/10.2337/diacare.26.3.725
50. Rahman M, Simmons RK, Harding AH, Wareham NJ, Griffin SJ. A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. Family Practice 2008;25:191-6. http://dx.doi.org/10.1093/fampra/cmn024
51. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880. http://dx.doi.org/10.1136/bmj.b880
52. Collins GS, Altman DG. External validation of QDSCORE(R) for predicting the 10-year risk of developing type 2 diabetes. Diabet Med 2011;28:599-607.
53. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000;16:164-71. http://dx.doi.org/10.1002/1520-7560(200005/06)16:3<164::AID-DMRR103>3.3.CO;2-I
54. Heldgaard PE, Griffin SJ. Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome. Diabet Med 2006;23:996-1002. http://dx.doi.org/ 10.1111/j.1464-5491.2006.01929.x
55. Witte DR, Shipley MJ, Marmot MG, Brunner EJ. Performance of existing risk scores in screening for undiagnosed diabetes: an external validation study. Diabet Med 2010;27:46-53. http://dx.doi.org/ 10.1111/j.1464-5491.2009.02891.x
56. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011;343:d7163. http://dx.doi.org/10.1136/bmj.d7163
57. Martin E, Ruf E, Landgraf R, Hauner H, Weinauer F, Martin S. FINDRISK questionnaire combined with HbA1c testing as a potential screening strategy for undiagnosed diabetes in a healthy population. Horm Metab Res 2011;43:782-7. http://dx.doi.org/10.1055/s-0031-1286333
58. Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AM, et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ 2012;345:e5900. http://dx.doi.org/10.1136/bmj.e5900
59. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ. What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? Diabetes screening programmes from a public health perspective. J Med Screen 2002;9:187-90. http://dx.doi.org/10.1136/jms.9.4.187
60. Paddison CA, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, et al. Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2009;339:b4535. http://dx.doi.org/ 10.1136/bmj.b4535
61. Qiao Q, Keinanen-Kiukaanniemi S, Rajala U, Uusimaki A, Kivela SL. Random capillary whole blood glucose test as a screening test for diabetes mellitus in a middle-aged population. Scand J Clin Lab Invest 1995;55:3-8.
62. Wareham NJ, Pfister R. Diabetes: glycated hemoglobin is a marker of diabetes and CVD risk. Nat Rev Cardiol 2010;7:367-8. http://dx.doi.org/10.1038/nrcardio.2010.84
63. Evans P, Langley P, Gray DP. Diagnosing type 2 diabetes before patients complain of diabetic symptoms: clinical opportunistic screening in a single general practice. Fam Pract 2008;25:376-81. http://dx.doi.org/10.1093/fampra/cmn052
64. Hu Y, Liu W, Chen Y, Zhang M, Wang L, Zhou H, et al. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. Acta Diabetol 2010;47:231-6. http://dx.doi.org/10.1007/s00592-009-0143-2
65. John WG, Hillson R, Alberti SG. Use of haemoglobin A1c (HbA1c) in the diagnosis of diabetes mellitus. The implementation of World Health Organization (WHO) guidance 2011. Practical Diabetes 2012;29:12-12a.
66. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):S5-20.
67. Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med 2004;141:475-6. http://dx.doi.org/10.7326/0003-4819-141-6-200409210-00014
68. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, et al. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? Diabetologia 2009;52:1279-89. http://dx.doi.org/10.1007/s00125-009-1360-5
69. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):62-9.
70. The International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
71. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11. http://dx.doi.org/10.1056/NEJMoa0908359
72. Peter A, Fritsche A, Stefan N, Heni M, Haring HU, Schleicher E. Diagnostic value of haemoglobin A1c for type 2 diabetes mellitus in a population at risk. Exp Clin Endocrinol Diabetes 2011; 119:23-7. http://dx.doi.org/10.1055/s-0030-1270440
73. Morrison G, Morrison CL, Purewal TS, Weston PJ. Evaluating the use of HbA1c in the diagnosis of diabetes compared with the oral glucose tolerance test in a primary care setting. Diabet Med 2011;28(Suppl. 1):113.
74. Schottker B, Raum E, Rothenbacher D, Muller H, Brenner H. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening. Eur J Epidemiol 2011;26:779-87. http://dx.doi.org/10.1007/s10654-011-9619-9
75. John WG. Haemoglobin A1c towards global standardization. Diabet Med 2010;27:733-4. http://dx.doi.org/10.1111/j.1464-5491.2010.03044.x
76. Bao Y, Ma X, Li H, Zhou M, Hu C, Wu H, et al. Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. BMJ 2010;340:c2249.
77. Kilpatrick ES, Winocour PH. ABCD position statement on haemoglobin A1c for the diagnosis of diabetes. Practical Diabetes Int 2010;27:306-10.
78. Schindhelm RK, Lenters-Westra E, Slingerland RJ. Glycated haemoglobin A(1c) (HbA1c) in the diagnosis of diabetes mellitus: don't forget the performance of the HbA1c assay. Diabet Med 2010;27:1214-15.
79. Scottish Public Health Network (SPHN). Type 2 Diabetes Needs Assessment. 2012. URL: www.scotphn.net/projects/previous_projects/type_2_diabetes_needs_assessment. Accessed 11 February 2012.
80. Cederberg H, Saukkonen T, Laakso M, Jokelainen J, Harkonen P, Timonen M, et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study. Diabetes Care 2010;33:2077-83. http://dx.doi.org/10.2337/ dc10-0262
81. Mostafa SA, Davies MJ, Webb D, Gray LJ, Srinivasan BT, Jarvis J, et al. The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus. Diabet Med 2010;27:762-9. http://dx.doi.org/10.1111/j.1464-5491.2010.03015.x
82. Mostafa SA, Srinivasan BT, Webb D, Sehmi S, Gray LJ, Yates T, et al. A comparison of incident Type 2 diabetes using WHO 1999 and the proposed HbA1cdiagnostic criteria in people with impaired glucose regulation (pre-diabetes): a prospective longitudinal follow-up study of a UK multi-ethnic cohort. Diabet Med 2011;28(Suppl. 1):188.
83. Borg R, Vistisen D, Witte DR, Borch-Johnsen K. Comparing risk profiles of individuals diagnosed with diabetes by OGTT and HbA1c. The Danish Inter99 study. Diabet Med 2010;27:906-10.
84. Lorenzo C, Wagenknecht LE, Hanley AJG, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010;33:2104-9. http://dx.doi.org/10.2337/dc10-0679
85. Valdes S, Botas P, Delgado E, Alvarez F, Diaz-Cadorniga F. HbA1c in the prediction of type 2 diabetes compared with fasting and 2-h post-challenge plasma glucose: the Asturias study (1998-2005). Diabetes Metab 2011;37:27-32.
86. Selvin E, Steffes MW, Bergenstal R, Coresh J, Brancati FL. 2010 American Diabetes Association (ADA) Cut-Points for Glycated Hemoglobin (A1c) and the Risk of Diabetes, Kidney, and Cardiovascular Disease. American Diabetes Association 70th Scientific Sessions, 2010, abstract no: 44-LB.
87. Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a followup study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. Diabetologia 2010;53:2328-33. http://dx.doi.org/ 10.1007/s00125-010-1867-9
88. Cosson E, Hamo-Tchatchouang E, Banu I, Nguyen MT, Chiheb S, Ba H, et al. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. Diabetes Metab 2010;36:312-18. http://dx.doi.org/ 10.1016/j.diabet.2010.02.004
89. Cavagnolli G, Comerlato J, Comerlato C, Renz PB, Gross JL, Camargo JL. HbA1c measurement for the diagnosis of diabetes: is it enough? Diabet Med 2011;28:31-5.
90. Pajunen P, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinanen-Kiukaanniemi S, et al. HbA1c in diagnosing and predicting type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabet Med 2010;28:36-42.
91. Bennett CM, Guo M, Dharmage SC. HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007;24:333-43.
92. Abdul-Ghani MA, DeFronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care 2009;32(Suppl.2):194-8. http://dx.doi.org/10.2337/dc09-S309
93. Joshipura KJ, Andriankaja MO, Hu FB, Ritchie CS. Relative utility of 1-h Oral Glucose Tolerance Test as a measure of abnormal glucose homeostasis. Diabetes Res Clin Pract 2011;93:268-75. http://dx.doi.org/10.1016/j.diabres.2011.05.035
94. Abdul-Ghani MA, Abdul-Ghani T, Muller G, Bergmann A, Fischer S, Bornstein S, et al. Role of glycated hemoglobin in the prediction of future risk of T2DM. J Clin Endocrinol Metab 2011;96:2596-600. http://dx.doi.org/10.1210/jc.2010-1698
95. Phillips LS, Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, et al. Glucose challenge test screening for prediabetes and undiagnosed diabetes. Diabetologia 2009;52:1798-807. http://dx.doi.org/10.1007/s00125-009-1407-7
96. Chatterjee R, Narayan KM, Lipscomb J, Phillips LS. Screening adults for pre-diabetes and diabetes may be cost-saving. Diabetes Care 2010;33:1484-90. http://dx.doi.org/10.2337/dc10-0054
97. Jones AG, Knight BA, Baker GC, Hattersley AT. Practical implications of choice of test in National Institute for Health and Clinical Excellence (NICE) guidance for the prevention of type 2 diabetes. Diabet Med 2013;30:126-7. http://dx.doi.org/10.1111/dme.12025
98. Carson AP, Reynolds K, Fonseca VA, Muntner P. Comparison of A1C and fasting glucose criteria to diagnose diabetes among U.S. adults. Diabetes Care 2010;33:95-7. http://dx.doi.org/10.2337/ dc09-1227
99. Mann DM, Carson AP, Shimbo D, Fonseca V, Fox CS, Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care 2010;33:2190-5. http://dx.doi. org/10.2337/dc10-0752
100. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC. Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 2000;17:433-40. http://dx.doi.org/ 10.1046/j.1464-5491.2000.00246.x
101. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 2001;285:2109-13. http://dx.doi.org/10.1001/jama.285.16.2109
102. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM, Prevost AT, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380:1741-8. http://dx.doi.org/10.1016/ S0140-6736(12)61422-6
103. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, et al. The association of HbA1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study. Diabetes 2010;59:2020-6.
104. Wang W, Lee ET, Howard BV, Fabsitz RR, Devereux RB, Welty TK. Fasting plasma glucose and HbA1c in identifying and predicting diabetes: the strong heart study. Diabetes Care 2011;34:363-8.
105. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, et al. Cigarette smoking and glycaemia: the EPIC-Norfolk Study. European Prospective Investigation into Cancer. Int J Epidemiol 2001;30:547-54.
106. Haffner S. M., Lorenzo C., and Laakso M. Performance characteristics of the 6.5% HbA1c threshold for detecting undiagnosed diabetes in Finnish men: the METabolic Syndrome In Men (METSIM) study. Proceedings of the American Diabetes Association 71st Scientific Sessions 1364-P. 2011.
107. Bobbert T, Mai K, Fischer-Rosinsky A, Pfeiffer AF, Spranger J. A1C is associated with intima-media thickness in individuals with normal glucose tolerance. Diabetes Care 2010;33:203-4. http://dx.doi. org/10.2337/dc09-1009
108. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010;33:2184-9. http://dx.doi.org/10.2337/dc10-0433
109. UKPDS Study Group. Ethnicity and cardiovascular disease. The incidence of myocardial infarction in white, South Asian, and Afro-Caribbean patients with type 2 diabetes (U.K. Prospective Diabetes Study 32). Diabetes Care 1998;21:1271-7.
110. Lipska KJ, De RN, Van Ness PH, Johnson KC, Kanaya A, Koster A, et al. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. J Clin Endocrinol Metab 2010;95:5289-95. http://dx.doi.org/10.1210/jc.2010-1171
111. Likhari T, Gama R. Ethnic differences in glycated haemoglobin between white subjects and those of South Asian origin with normal glucose tolerance. J Clin Pathol 2010;63:278-80. http://dx.doi.org/ 10.1136/jcp.2009.065821
112. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-7. http://dx.doi.org/10.2337/dc06-2003
113. Gerstein HC, Islam S, Anand S, Almahmeed W, Damasceno A, Dans A, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia 2010;53:2509-17. http://dx.doi.org/10.1007/s00125-010-1871-0
114. Webb DR, Gray LJ, Khunti K, Srinivasan B, Taub N, Campbell S, et al. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia 2011;54:2237-46. http://dx.doi. org/10.1007/s00125-011-2189-2
115. Brindle P, May M, Gill P, et al. ETHRISK: A modified Framingham CHD and CVD risk calculator for British black and minority ethnic groups. University of Bristol, UK. Available at: http://www.epi.bris. ac.uk/CVDethrisk (last accessed January 2012).
116. Bhopal RS. A four-stage model explaining the higher risk of type 2 diabetes mellitus in South Asians compared with European populations. Diabet Med 2013;30:35-42. http://dx.doi.org/10.1111/ dme.12016
117. Szczepura A. Nutrition in an ethnically diverse society: what are some of the key challenges? Proc Nutr Soc 2011;70:252-62. http://dx.doi.org/10.1017/S0029665111000085
118. Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care 2010;33:2016-17. http://dx.doi.org/10.2337/dc10-0588
119. Davies M, Day J. Screening for non-insulin-dependent diabetes mellitus (NIDDM): how often should it be performed? J Med Screen 1994;1:78-81.
120. The ADDITION Study Group. Protocol, ADDITION (Anglo-Danish-Dutch Study in General Practice of Intensive Treatment and Complication Prevention in Type 2 Diabetic Patients Identified by Screening) study. 2005. www.addition.au.dk/Protocol%20-%20ADDITION.pdf. Accessed 16 February 2012.
121. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Dis 2000;24(Suppl. 3):6-11. http://dx.doi.org/10.1038/sj.ijo.0801420
122. van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, et al. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study. Diabet Med 2011;28:1416-24. http://dx.doi.org/10.1111/j.1464-5491.2011.03365.x
123. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbaek A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378:156-67. http://dx.doi.org/10.1016/S0140-6736(11)60698-3
124. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008;51:1127-34. http://dx.doi.org/10.1007/s00125-008-1013-0
125. Barakat A, Williams KM, Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ, et al. Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort. Diabet Med 2013;30:233-8. http://dx.doi.org/ 10.1111/j.1464-5491.2012.03765.x
126. Eborall H, Davies R, Kinmonth AL, Griffin S, Lawton J. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007;335:490. http://dx.doi.org/10.1136/bmj.39308.392176.BE
127. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
128. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
129. Absetz P, Oldenburg B, Hankonen N, Valve R, Heinonen H, Nissinen A, et al. Type 2 diabetes prevention in the real world: three-year results of the GOAL lifestyle implementation trial. Diabetes Care 2009;32:1418-20. http://dx.doi.org/10.2337/dc09-0039
130. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database Syst Rev 2005;2:CD005270. http://dx.doi.org/10.1002/14651858.CD005270
131. Perry IJ, Villegas R, Salim A, Flynn A. Clustering of protective factors for glucose intolerance and insulin resistance: a cross-sectional study. Diabet Med 2005;22:1091-7. http://dx.doi.org/10.1111/ j.1464-5491.2005.01617.x
132. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992;16:397-415.
133. United Nations Statistics Division. Millennium development goals indicators. The official United Nations site for the MDG indicators. 2012. URL: http://unstats.un.org/unsd/mdg/SeriesDetail.aspx? srid=699. Accessed 20 June 2012.
134. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. ABC of arterial and venous disease: vascular complications of diabetes. BMJ 2000;320:1062-6. http://dx.doi.org/10.1136/bmj.320.7241.1062
135. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes mellitus decreasing? Am J Epidemiol 2009;169:455-61. http://dx.doi.org/10.1093/aje/kwn342
136. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20. http://dx.doi.org/10.1177/0272989X06290495
137. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005;143:251-64. http://dx.doi.org/ 10.7326/0003-4819-143-4-200508160-00006
138. Feenstra TL, van Baal PM, Jacobs-van der Bruggen MO, Hoogenveen RT, Kommer GJ, Baan CA. Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention. Cost Eff Resour Alloc 2011;9:14. http://dx.doi.org/10.1186/1478-7547-9-14
139. Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Affairs 2008;27:256-68. http://dx.doi.org/10.1377/hlthaff.27.1.256
140. Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Griffin SJ. Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of type 2 diabetes: a modelling study. Diabet Med 2012;29:893-904. http://dx.doi.org/10.1111/j.1464-5491.2012.03609.x
141. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80:95-103.
142. University of Leicester. UK National Screening Committee. Handbook for vascular risk assessment, risk reduction and risk management. 2008. URL: www.screening.nhs.uk/getdata.php?id=9051. Accessed 16 February 2012.
143. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008;336:1180-5. http://dx.doi.org/10.1136/bmj.39545.585289.25
144. Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy 2010;8:191-202. http://dx.doi.org/10.2165/ 11532880-000000000-00000
145. Davies MJ, Tringham JR, Jarvis J, Skinner TC, Farooqi AM, Khunti K. Systematic screening for type 2 diabetes mellitus: results of a large population based study targeting those with conventional risk factors. Diabet Med 2005;22(Suppl. 2):99.
146. Davis TM. Ethnic diversity in type 2 diabetes. Diabet Med 2008;25(Suppl. 2):52-6. http://dx.doi.org/ 10.1111/j.1464-5491.2008.02499.x
147. Icks A, Haastert B, Gandjour A, John J, Lowel H, Holle R, et al. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000. Diabetes Care 2004;27:2120-8. http://dx.doi.org/10.2337/diacare.27.9.2120
148. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83. http://dx.doi.org/10.1136/bmj.313.7052.275
149. Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia 2010;53:875-81. http://dx.doi.org/10.1007/s00125-010-1661-8
150. Hoerger TJ, Hicks KA, Sorensen SW, Herman WH, Ratner RE, Ackermann RT, et al. Costeffectiveness of screening for pre-diabetes among overweight and obese U.S. adults. Diabetes Care 2007;30:2874-9. http://dx.doi.org/10.2337/dc07-0885
151. Chatterton H, Younger T, Fischer A, Khunti K. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ 2012;345:e4624. http://dx.doi.org/ 10.1136/bmj.e4624
152. Chamnan P, Simmons RK, Forouhi NG, Luben RN, Khaw KT, Wareham NJ, et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the European prospective investigation of cancer-Norfolk cohort: implications for preventive strategies. Diabetes Care 2011;34:950-6. http://dx.doi.org/10.2337/dc09-2326
153. Pereira Gray DJ, Evans PH, Wright C, Langley P. The cost of diagnosing type 2 diabetes mellitus by clinical opportunistic screening in general practice. Diabet Med 2012;29:863-8. http://dx.doi.org/ 10.1111/j.1464-5491.2012.03607.x
154. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 2007;30:1120-4. http://dx.doi.org/10.2337/dc06-2377
155. Khunti K, Davies M. Should we screen for type 2 diabetes? Yes. BMJ 2012;345:e4514. http://dx.doi. org/10.1136/bmj.e4514
156. Goyder E, Irwig L, Payne N. Should we screen for type 2 diabetes? No. BMJ 2012;345:e4516. http://dx.doi.org/10.1136/bmj.e4516
157. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27(Suppl. 1): 11-14.
158. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl. 1):1-201.
159. New Zealand Society for the Study of Diabetes. NZSSD Position Statement on Screening and Type 2 Diabetes. 2009. URL: www.nzssd.org.nz/position_statements/screening.html. Accessed 1 September 2012.
160. National Institute for Health and Clinical Excellence (NICE). Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. NICE public health guidance 38. 2012. URL: www.nice.org.uk/nicemedia/live/13791/59951/59951.pdf. Accessed 1 September 2012.
161. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 8th edn. 2012. URL: www.racgp.org.au/download/Documents/Guidelines/Redbook8/ redbook8.pdf. Accessed 1 September 2012.
162. Smith S, Waterall J, Burden AC. An evaluation of the performance of the NHS Health Check programme in identifying people at high risk of developing type 2 diabetes. BMJ Open 2013;3(3). http://dx.doi.org/10.1136/bmjopen-2012-002219
163. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. Guideline No. 97. February 2007.